COVID-19 in patients with systemic lupus erythematosus: A systematic review. (May 2022)

• Record Type: Journal Article
• Authors: Fu, Xue-Lei; Qian, Yan; Jin, Xiao-Hong; Yu, Hai-Rong; Du, Lin; Wu, Hua; Chen, Hong-Lin; Shi, Ya-Qin
• Is Part Of: Lupus. Volume 31:Number 6(2022)
• Page Start: 684
• Page End: 696
• Publication Date: 2022-05
• Subjects: SLE -- COVID-19 -- SARS-CoV-2 -- Systematic Review; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/09612033221093502
• Languages: English
• ISSNs: 0961-2033

Abstract

The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.